Scott E. Eggener to Watchful Waiting
This is a "connection" page, showing publications Scott E. Eggener has written about Watchful Waiting.
Connection Strength
5.111
-
Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.
Score: 0.761
-
Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252.
Score: 0.634
-
Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883.
Score: 0.500
-
How active should active surveillance be? BJU Int. 2015 Feb; 115(2):176-7.
Score: 0.475
-
National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102.
Score: 0.459
-
Editorial comment. J Urol. 2014 Jul; 192(1):81.
Score: 0.448
-
Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.
Score: 0.446
-
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25.
Score: 0.411
-
Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023 07; 210(1):38-45.
Score: 0.210
-
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 07; 208(1):19-25.
Score: 0.197
-
"Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709.
Score: 0.153
-
Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249.
Score: 0.138
-
Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34.
Score: 0.120
-
Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7.
Score: 0.119
-
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119.
Score: 0.041